

NCHA Financial Feature



November 2, 2018

CMS Finalizes Calendar Year 2019 Payments and 2020 Policy Changes for Home Health Agencies and Home Infusion Therapy Suppliers

The Centers for Medicare and Medicaid Services (CMS) has issued a final calendar year (CY) 2019 update to the home health prospective payment system (HH PPS).

The 682-page rule is currently on display at the **Federal Register**. A copy is at: <https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-24145.pdf>. Publication is slated for November 13th.

The rule will update both the payment rates and case-mix weights for home health agencies (HHAs) for CY 2019.

For home health services beginning on or after Jan. 1, 2020, the rule finalizes a case-mix methodology refinement, which will eliminate the use of therapy thresholds for case-mix adjustment purposes; and will change the unit of payment from a 60-day episode of care to a 30-day period of care, as mandated by section 51001 of the **Bipartisan Budget Act of 2018** (BBA).

The rule also contains a new methodology used to determine rural add-on payments for CYs 2019 through 2022 as mandated by statute. Further, the rule will establish a transitional payment for home infusion therapy services for CYs 2019 and 2020, again as mandated by law.

Comment

CMS provides the following table regarding cost, transfers and benefits.

| Provision Description | Costs and Cost Savings | Transfers | Benefits |
|--|------------------------|---|--|
| CY 2019 HH PPS Payment Rate Update | | The overall economic impact of the HH PPS payment rate update is an estimated \$420 million (2.2 percent) in increased payments in CY 2019. | To ensure home health payments are consistent with statutory payment authority for CY 2019. |
| CY 2019 Temporary Transitional Payments for Home Infusion Therapy Services | | The overall economic impact of the temporary transitional payment for home infusion therapy services is an estimated \$60 million in increased payments to home infusion therapy suppliers in CY 2019 (\$48 million in Medicare payments and \$12 million in beneficiary cost-sharing). | To ensure temporary transitional payments for home infusion therapy are consistent with statutory authority for CY 2019. |

| Provision Description | Costs and Cost Savings | Transfers | Benefits |
|--|---|---|--|
| CY 2019 HHVBP Model | | The overall economic impact of the HHVBP Model for CY 2018 through 2022 is an estimated \$378 million in total savings to Medicare from a reduction in unnecessary hospitalizations and SNF usage as a result of greater quality improvements in the HH industry (none of which is attributable to the changes in this final rule). As for payments to HHAs, there are no aggregate increases or decreases expected to be applied to the HHAs competing in the model. | |
| CY 2020 OASIS Changes | The overall economic impact of the HH QRP and the case-mix adjustment methodology changes is annual savings to HHAs of an estimated \$60 million. | | A reduction in burden to HHAs of approximately 73 hours annually for a savings of approximately \$5,150 annually per HHA. |
| CY 2020 Case-Mix Adjustment Methodology Changes, Including a Change in the Unit of Service from 60 to 30 days. | | The overall economic impact of the case-mix adjustment methodology changes, including a change in the unit of service from 60 to 30 days, for CY 2020 results in no estimated dollar impact to HHAs, as section 51001(a) of the BBA requires such change to be implemented in a budget-neutral manner. | To ensure home health payments are consistent with statutory payment authority for CY 2020. |
| Accreditation for Home Infusion Therapy suppliers | <p>The cost related to an Accrediting Organization obtaining CMS approval of a home infusion therapy accreditation program is estimated to be \$8,014.50 per each AO, for AOs that have previously submitted an accreditation application to CMS.</p> <p>The cost related to each home infusion therapy AO for obtaining CMS approval of a home infusion therapy accreditation program is estimated to be \$12,453 per each AO, for AOs that have not previously submitted an accreditation application to CMS.</p> | | <p>Accreditation of HIT suppliers will be required in order for HIT suppliers to receive payment from Medicare, effective 01/01/2021.</p> <p>The CMSAO approval and oversight regulations are necessary so that CMS has a process in place for the approval and oversight of the AOs that will be CMS-approved home infusion therapy accrediting organizations available to accredit the home infusion therapy suppliers, so that they can continue to receive payment from Medicare when the permanent benefits go into effect on 01/01/2021.</p> |

The rule has a very limited table of contents. There are no page numbers. Page numbers cited below are based on Adobe Acrobat counting. There is no table/list of acronyms.

On a positive side, CMS has provided “final decision” sections.

1. CY 2019 HH PPS Case-Mix Weights

The final CY 2019 case-mix weights are shown in the table below. There are 153 weights comprising the home health resource groups (HHRGs).

CY 2019 Case-Mix Payment Weights

| Pay Group | Description | Clinical and Functional Levels (1 = Low; 2 = Medium; 3= High) | CY 2019 Weights |
|-----------|---|--|-----------------|
| 10111 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C1F1S1 | 0.5468 |
| 10112 | 1st and 2nd Episodes, 6 Therapy Visits | C1F1S2 | 0.6791 |
| 10113 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C1F1S3 | 0.8115 |
| 10114 | 1st and 2nd Episodes, 10 Therapy Visits | C1F1S4 | 0.9438 |
| 10115 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C1F1S5 | 1.0761 |
| 21111 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C1F1S1 | 1.2085 |
| 21112 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C1F1S2 | 1.3526 |
| 21113 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C1F1S3 | 1.4968 |
| 10121 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C1F2S1 | 0.6473 |
| 10122 | 1st and 2nd Episodes, 6 Therapy Visits | C1F2S2 | 0.7651 |
| 10123 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C1F2S3 | 0.8829 |
| 10124 | 1st and 2nd Episodes, 10 Therapy Visits | C1F2S4 | 1.0007 |
| 10125 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C1F2S5 | 1.1185 |
| 21121 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C1F2S1 | 1.2363 |
| 21122 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C1F2S2 | 1.3858 |
| 21123 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C1F2S3 | 1.5352 |
| 10131 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C1F3S1 | 0.6885 |
| 10132 | 1st and 2nd Episodes, 6 Therapy Visits | C1F3S2 | 0.8013 |
| 10133 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C1F3S3 | 0.9140 |
| 10134 | 1st and 2nd Episodes, 10 Therapy Visits | C1F3S4 | 1.0268 |
| 10135 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C1F3S5 | 1.1396 |
| 21131 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C1F3S1 | 1.2523 |
| 21132 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C1F3S2 | 1.3992 |
| 21133 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C1F3S3 | 1.5460 |
| 10211 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C2F1S1 | 0.5769 |
| 10212 | 1st and 2nd Episodes, 6 Therapy Visits | C2F1S2 | 0.7176 |
| 10213 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C2F1S3 | 0.8584 |
| 10214 | 1st and 2nd Episodes, 10 Therapy Visits | C2F1S4 | 0.9991 |
| 10215 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C2F1S5 | 1.1398 |
| 21211 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C2F1S1 | 1.2806 |
| 21212 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C2F1S2 | 1.4321 |
| 21213 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C2F1S3 | 1.5836 |
| 10221 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C2F2S1 | 0.6773 |
| 10222 | 1st and 2nd Episodes, 6 Therapy Visits | C2F2S2 | 0.8035 |
| 10223 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C2F2S3 | 0.9298 |
| 10224 | 1st and 2nd Episodes, 10 Therapy Visits | C2F2S4 | 1.0560 |
| 10225 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C2F2S5 | 1.1822 |
| 21221 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C2F2S1 | 1.3084 |
| 21222 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C2F2S2 | 1.4653 |
| 21223 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C2F2S3 | 1.6221 |

| Pay Group | Description | Clinical and Functional Levels (1 = Low; 2 = Medium; 3= High) | CY 2019 Weights |
|-----------|---|--|-----------------|
| 10231 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C2F3S1 | 0.7186 |
| 10232 | 1st and 2nd Episodes, 6 Therapy Visits | C2F3S2 | 0.8397 |
| 10233 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C2F3S3 | 0.9609 |
| 10234 | 1st and 2nd Episodes, 10 Therapy Visits | C2F3S4 | 1.0821 |
| 10235 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C2F3S5 | 1.2033 |
| 21231 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C2F3S1 | 1.3244 |
| 21232 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C2F3S2 | 1.4787 |
| 21233 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C2F3S3 | 1.6329 |
| 10311 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C3F1S1 | 0.6294 |
| 10312 | 1st and 2nd Episodes, 6 Therapy Visits | C3F1S2 | 0.7799 |
| 10313 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C3F1S3 | 0.9304 |
| 10314 | 1st and 2nd Episodes, 10 Therapy Visits | C3F1S4 | 1.0809 |
| 10315 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C3F1S5 | 1.2314 |
| 21311 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C3F1S1 | 1.3819 |
| 21312 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C3F1S2 | 1.5782 |
| 21313 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C3F1S3 | 1.7746 |
| 10321 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C3F2S1 | 0.7298 |
| 10322 | 1st and 2nd Episodes, 6 Therapy Visits | C3F2S2 | 0.8658 |
| 10323 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C3F2S3 | 1.0018 |
| 10324 | 1st and 2nd Episodes, 10 Therapy Visits | C3F2S4 | 1.1378 |
| 10325 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C3F2S5 | 1.2737 |
| 21321 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C3F2S1 | 1.4097 |
| 21322 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C3F2S2 | 1.6114 |
| 21323 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C3F2S3 | 1.8130 |
| 10331 | 1st and 2nd Episodes, 0 to 5 Therapy Visits | C3F3S1 | 0.7711 |
| 10332 | 1st and 2nd Episodes, 6 Therapy Visits | C3F3S2 | 0.9020 |
| 10333 | 1st and 2nd Episodes, 7 to 9 Therapy Visits | C3F3S3 | 1.0329 |
| 10334 | 1st and 2nd Episodes, 10 Therapy Visits | C3F3S4 | 1.1639 |
| 10335 | 1st and 2nd Episodes, 11 to 13 Therapy Visits | C3F3S5 | 1.2948 |
| 21331 | 1st and 2nd Episodes, 14 to 15 Therapy Visits | C3F3S1 | 1.4258 |
| 21332 | 1st and 2nd Episodes, 16 to 17 Therapy Visits | C3F3S2 | 1.6248 |
| 21333 | 1st and 2nd Episodes, 18 to 19 Therapy Visits | C3F3S3 | 1.8238 |
| 30111 | 3rd+ Episodes, 0 to 5 Therapy Visits | C1F1S1 | 0.4691 |
| 30112 | 3rd+ Episodes, 6 Therapy Visits | C1F1S2 | 0.6147 |
| 30113 | 3rd+ Episodes, 7 to 9 Therapy Visits | C1F1S3 | 0.7603 |
| 30114 | 3rd+ Episodes, 10 Therapy Visits | C1F1S4 | 0.9059 |
| 30115 | 3rd+ Episodes, 11 to 13 Therapy Visits | C1F1S5 | 1.0515 |
| 22111 | 3rd+ Episodes, 14 to 15 Therapy Visits | C1F1S1 | 1.1971 |
| 22112 | 3rd+ Episodes, 16 to 17 Therapy Visits | C1F1S2 | 1.3451 |
| 22113 | 3rd+ Episodes, 18 to 19 Therapy Visits | C1F1S3 | 1.4930 |
| 40111 | All Episodes, 20+ Therapy Visits | C1F1S1 | 1.6409 |
| 30121 | 3rd+ Episodes, 0 to 5 Therapy Visits | C1F2S1 | 0.5514 |
| 30122 | 3rd+ Episodes, 6 Therapy Visits | C1F2S2 | 0.6936 |
| 30123 | 3rd+ Episodes, 7 to 9 Therapy Visits | C1F2S3 | 0.8358 |
| 30124 | 3rd+ Episodes, 10 Therapy Visits | C1F2S4 | 0.9780 |
| 30125 | 3rd+ Episodes, 11 to 13 Therapy Visits | C1F2S5 | 1.1202 |
| 22121 | 3rd+ Episodes, 14 to 15 Therapy Visits | C1F2S1 | 1.2624 |
| 22122 | 3rd+ Episodes, 16 to 17 Therapy Visits | C1F2S2 | 1.4031 |
| 22123 | 3rd+ Episodes, 18 to 19 Therapy Visits | C1F2S3 | 1.5439 |
| 40121 | All Episodes, 20+ Therapy Visits | C1F2S1 | 1.6847 |
| 30131 | 3rd+ Episodes, 0 to 5 Therapy Visits | C1F3S1 | 0.5884 |
| 30132 | 3rd+ Episodes, 6 Therapy Visits | C1F3S2 | 0.7232 |
| 30133 | 3rd+ Episodes, 7 to 9 Therapy Visits | C1F3S3 | 0.8580 |

| Pay Group | Description | Clinical and Functional Levels (1 = Low; 2 = Medium; 3= High) | CY 2019 Weights |
|-----------|--|--|-----------------|
| 30134 | 3rd+ Episodes, 10 Therapy Visits | C1F3S4 | 0.9928 |
| 30135 | 3rd+ Episodes, 11 to 13 Therapy Visits | C1F3S5 | 1.1276 |
| 22131 | 3rd+ Episodes, 14 to 15 Therapy Visits | C1F3S1 | 1.2624 |
| 22132 | 3rd+ Episodes, 16 to 17 Therapy Visits | C1F3S2 | 1.4058 |
| 22133 | 3rd+ Episodes, 18 to 19 Therapy Visits | C1F3S3 | 1.5493 |
| 40131 | All Episodes, 20+ Therapy Visits | C1F3S1 | 1.6928 |
| 30211 | 3rd+ Episodes, 0 to 5 Therapy Visits | C2F1S1 | 0.4930 |
| 30212 | 3rd+ Episodes, 6 Therapy Visits | C2F1S2 | 0.6480 |
| 30213 | 3rd+ Episodes, 7 to 9 Therapy Visits | C2F1S3 | 0.8030 |
| 30214 | 3rd+ Episodes, 10 Therapy Visits | C2F1S4 | 0.9579 |
| 30215 | 3rd+ Episodes, 11 to 13 Therapy Visits | C2F1S5 | 1.1129 |
| 22211 | 3rd+ Episodes, 14 to 15 Therapy Visits | C2F1S1 | 1.2679 |
| 22212 | 3rd+ Episodes, 16 to 17 Therapy Visits | C2F1S2 | 1.4236 |
| 22213 | 3rd+ Episodes, 18 to 19 Therapy Visits | C2F1S3 | 1.5794 |
| 40211 | All Episodes, 20+ Therapy Visits | C2F1S1 | 1.7352 |
| 30221 | 3rd+ Episodes, 0 to 5 Therapy Visits | C2F2S1 | 0.5753 |
| 30222 | 3rd+ Episodes, 6 Therapy Visits | C2F2S2 | 0.7269 |
| 30223 | 3rd+ Episodes, 7 to 9 Therapy Visits | C2F2S3 | 0.8784 |
| 30224 | 3rd+ Episodes, 10 Therapy Visits | C2F2S4 | 1.0300 |
| 30225 | 3rd+ Episodes, 11 to 13 Therapy Visits | C2F2S5 | 1.1815 |
| 22221 | 3rd+ Episodes, 14 to 15 Therapy Visits | C2F2S1 | 1.3331 |
| 22222 | 3rd+ Episodes, 16 to 17 Therapy Visits | C2F2S2 | 1.4817 |
| 22223 | 3rd+ Episodes, 18 to 19 Therapy Visits | C2F2S3 | 1.6303 |
| 40221 | All Episodes, 20+ Therapy Visits | C2F2S1 | 1.7790 |
| 30231 | 3rd+ Episodes, 0 to 5 Therapy Visits | C2F3S1 | 0.6123 |
| 30232 | 3rd+ Episodes, 6 Therapy Visits | C2F3S2 | 0.7565 |
| 30233 | 3rd+ Episodes, 7 to 9 Therapy Visits | C2F3S3 | 0.9006 |
| 30234 | 3rd+ Episodes, 10 Therapy Visits | C2F3S4 | 1.0448 |
| 30235 | 3rd+ Episodes, 11 to 13 Therapy Visits | C2F3S5 | 1.1889 |
| 22231 | 3rd+ Episodes, 14 to 15 Therapy Visits | C2F3S1 | 1.3331 |
| 22232 | 3rd+ Episodes, 16 to 17 Therapy Visits | C2F3S2 | 1.4844 |
| 22233 | 3rd+ Episodes, 18 to 19 Therapy Visits | C2F3S3 | 1.6357 |
| 40231 | All Episodes, 20+ Therapy Visits | C2F3S1 | 1.7871 |
| 30311 | 3rd+ Episodes, 0 to 5 Therapy Visits | C3F1S1 | 0.5942 |
| 30312 | 3rd+ Episodes, 6 Therapy Visits | C3F1S2 | 0.7644 |
| 30313 | 3rd+ Episodes, 7 to 9 Therapy Visits | C3F1S3 | 0.9347 |
| 30314 | 3rd+ Episodes, 10 Therapy Visits | C3F1S4 | 1.1049 |
| 30315 | 3rd+ Episodes, 11 to 13 Therapy Visits | C3F1S5 | 1.2752 |
| 22311 | 3rd+ Episodes, 14 to 15 Therapy Visits | C3F1S1 | 1.4454 |
| 22312 | 3rd+ Episodes, 16 to 17 Therapy Visits | C3F1S2 | 1.6206 |
| 22313 | 3rd+ Episodes, 18 to 19 Therapy Visits | C3F1S3 | 1.7957 |
| 40311 | All Episodes, 20+ Therapy Visits | C3F1S1 | 1.9709 |
| 30321 | 3rd+ Episodes, 0 to 5 Therapy Visits | C3F2S1 | 0.6765 |
| 30322 | 3rd+ Episodes, 6 Therapy Visits | C3F2S2 | 0.8433 |
| 30323 | 3rd+ Episodes, 7 to 9 Therapy Visits | C3F2S3 | 1.0102 |
| 30324 | 3rd+ Episodes, 10 Therapy Visits | C3F2S4 | 1.1770 |
| 30325 | 3rd+ Episodes, 11 to 13 Therapy Visits | C3F2S5 | 1.3438 |
| 22321 | 3rd+ Episodes, 14 to 15 Therapy Visits | C3F2S1 | 1.5106 |
| 22322 | 3rd+ Episodes, 16 to 17 Therapy Visits | C3F2S2 | 1.6787 |
| 22323 | 3rd+ Episodes, 18 to 19 Therapy Visits | C3F2S3 | 1.8467 |
| 40321 | All Episodes, 20+ Therapy Visits | C3F2S1 | 2.0147 |
| 30331 | 3rd+ Episodes, 0 to 5 Therapy Visits | C3F3S1 | 0.7135 |
| 30332 | 3rd+ Episodes, 6 Therapy Visits | C3F3S2 | 0.8729 |

| Pay Group | Description | Clinical and Functional Levels (1 = Low; 2 = Medium; 3= High) | CY 2019 Weights |
|-----------|--|--|-----------------|
| 30333 | 3rd+ Episodes, 7 to 9 Therapy Visits | C3F3S3 | 1.0324 |
| 30334 | 3rd+ Episodes, 10 Therapy Visits | C3F3S4 | 1.1918 |
| 30335 | 3rd+ Episodes, 11 to 13 Therapy Visits | C3F3S5 | 1.3512 |
| 22331 | 3rd+ Episodes, 14 to 15 Therapy Visits | C3F3S1 | 1.5106 |
| 22332 | 3rd+ Episodes, 16 to 17 Therapy Visits | C3F3S2 | 1.6814 |
| 22333 | 3rd+ Episodes, 18 to 19 Therapy Visits | C3F3S3 | 1.8521 |
| 40331 | All Episodes, 20+ Therapy Visits | C3F3S1 | 2.0228 |

(Note the pay groups above are not in order as has been done in prior years.)

2. CY 2019 Rate Update

a. Rebasing and Revising of the Home Health Market Basket – Labor Share

CMS is rebasing and revising the HH market basket. Effective for CY 2019. The labor-related share will be 76.1 percent and the non-labor-related share will be 23.9 percent. The current labor-related share is 78.5 percent and the non-labor-related share is 21.5 percent.

b. CY 2019 Market Basket Update for HHAs

The home health market basket for CY 2019 is 3.0 percent. CMS is reducing this percentage increase by the current estimate of the multi-factor productivity (MFP) adjustment of 0.8 percent resulting in net increase of 2.2 percent.

The home health update will be decreased by 2.0 percentage points for those HHAs that do not submit quality data. For HHAs that do not submit the required quality data for CY 2019, the home health payment update will be 0.2 percent (2.2 percent minus 2.0 percentage points).

c. CY 2019 Home Health Wage Index

The CY 2019 wage index is available on the CMS website at: <https://go.cms.gov/20r9vHN>.

The CY 2019 wage index budget neutrality factor is 0.9985

d. CY 2019 Annual Payment Update

The CY 2019 national, standardized 60-day episode payment rate is calculated as follows:

CY 2019 60-day National, Standardized 60-Day Episode Payment Amount

| CY 2018 National, Standardized 60-Day Episode Payment | Wage Index Budget Neutrality Factor | Case-Mix Weights Budget Neutrality Factor | CY 2019 HH Payment Update | CY 2019 National, Standardized 60-Day Episode Payment |
|---|-------------------------------------|---|---------------------------|---|
| \$3,039.64 | X 0.9985 | X 1.0169 | X 1.022 | \$3,154.27 |

CY 2019 60-day National, Standardized 60-Day Episode Payment Amount for HHAs that DO NOT Submit the Quality Data

| CY 2018 National, Standardized 60-Day Episode Payment | Wage Index Budget Neutrality Factor | Case-Mix Weights Budget Neutrality Factor | CY 2019 HH Payment Update Minus 2 Percentage Points | CY 2019 National, Standardized 60-Day Episode Payment |
|---|-------------------------------------|---|---|---|
| \$3,039.64 | X 0.9985 | X 1.0169 | X 1.002 | \$3,092.55 |

e. CY 2018 National Per-Visit Rates

The national per-visit rates are used to pay the Low-Utilization Payment Adjustment (LUPA) (episodes with four or fewer visits) and are also used to compute imputed costs in outlier calculations. The per-visit rates are paid by type of visit or HH discipline. The six HH disciplines are as follows:

- Home health aide (HH aide);
- Medical Social Services (MSS);
- Occupational therapy (OT);
- Physical therapy (PT);
- Skilled nursing (SN); and
- Speech-language pathology (SLP).

CY 2019 National Per-Visit Payment Amounts for HHAs That DO Submit the Required Quality Data

| HH Discipline Type | CY 2018 Per-Visit Payment | Wage Index Budget Neutrality Factor | CY 2019 HH Payment Update | CY 2019 Per-Visit Payment |
|-----------------------------------|---------------------------|-------------------------------------|---------------------------|---------------------------|
| Home Health Aide | \$ 64.94 | X 0.9996 | X 1.022 | \$ 66.34 |
| Medical Social Services | \$229.86 | X 0.9996 | X 1.022 | \$234.82 |
| Occupational Therapy | \$157.83 | X 0.9996 | X 1.022 | \$161.24 |
| Physical Therapy | \$156.76 | X 0.9996 | X 1.022 | \$160.14 |
| Skilled Nursing | \$143.40 | X 0.9996 | X 1.022 | \$146.50 |
| Speech- Language Pathology | \$170.38 | X 0.9996 | X 1.022 | \$174.06 |

CY 2019 National Per-Visit Payment Amounts for HHAs That DO NOT Submit the Required Quality Data

| HH Discipline Type | CY 2018 Per-Visit Rates | Wage Index Budget Neutrality Factor | CY 2019 HH Payment Update Minus 2 Percentage Points | CY 2019 Per-Visit Rates |
|----------------------------|-------------------------|-------------------------------------|---|-------------------------|
| Home Health Aide | \$ 64.94 | X 0.9996 | X 1.002 | \$ 65.04 |
| Medical Social Services | \$229.86 | X 0.9996 | X 1.002 | \$230.23 |
| Occupational Therapy | \$157.83 | X 0.9996 | X 1.002 | \$158.08 |
| Physical Therapy | \$156.76 | X 0.9996 | X 1.002 | \$157.01 |
| Skilled Nursing | \$143.40 | X 0.9996 | X 1.002 | \$143.63 |
| Speech- Language Pathology | \$170.38 | X 0.9996 | X 1.002 | \$170.65 |

f. CY 2019 Non-routine Medical Supply (NRS) Payment Rates

Payments for NRS are computed by multiplying the relative weight for a particular severity level by the NRS conversion factor.

CY 2019 NRS Conversion Factor for HHAs that DO Submit the Required Quality Data

| CY 2018 NRS Conversion Factor | CY 2019 HH Payment Update | CY 2019 NRS Conversion Factor |
|-------------------------------|---------------------------|-------------------------------|
| \$53.03 | X 1.022 | \$54.20 |

CY 2019 NRS Payment Amounts for HHAs that DO Submit the Required Quality Data

| Severity Level | Points (Scoring) | Relative Weight | CY 2019 NRS Payment Amounts |
|----------------|------------------|-----------------|-----------------------------|
| 1 | 0 | 0.2698 | \$ 14.62 |
| 2 | 1 to 14 | 0.9742 | \$ 52.80 |
| 3 | 15 to 27 | 2.6712 | \$ 144.78 |
| 4 | 28 to 48 | 3.9686 | \$ 215.10 |
| 5 | 49 to 98 | 6.1198 | \$ 331.69 |
| 6 | 99+ | 10.5254 | \$ 570.48 |

For non-quality reporters see the rule's tables 22 and 23.

g. Rural Add-on Payments for CYs 2019 through 2022

The **BBA**, provides that rural counties (or equivalent areas) would be placed into one of three categories for purposes of the HH rural add-on payments: (1) rural counties and equivalent areas in the highest quartile of all counties and equivalent areas based on the number of Medicare home health episodes furnished per 100 individuals who are entitled to, or enrolled for, benefits under part A of Medicare or enrolled for benefits under part B of Medicare only, but not enrolled in a Medicare Advantage plan under part C of Medicare; (2) rural counties and equivalent areas with a population density of 6 individuals or fewer per square mile of land area; and (3) rural counties and equivalent areas not in the categories above; i.e., all others.

In the proposed rule, CMS said it would classify 510 rural counties or equivalent areas into the "High utilization" category. CMS stated that there are 334 rural counties or equivalent areas that have a

population density of six individuals or fewer per square mile of land area and that are not already classified into the “High utilization” category. CMS said that there are 1,162 remaining rural counties and equivalent areas that do not meet the criteria for inclusion in the “High utilization” or “Low population density” categories. CMS proposed to classify these 1,162 rural counties and equivalent areas into the “All other” category. Two thousand six (2006) counties are considered rural for purposes of determining HH rural add-on payments. CMS has not included any revised numbers in this final rule.

The rural add-ons will be, as proposed, as follows;

| Category | CY 2019 | CY 2020 | CY 2021 | CY 2022 |
|------------------------|---------|---------|---------|---------|
| High utilization | 1.5% | 0.5% | | |
| Low population density | 4.0% | 3.0% | 2.0% | 1.0% |
| All other | 3.0% | 2.0% | 1.0% | |

CMS will require HHAs to enter the FIPS state and county code, rather than the SSA state and county code, on the claim.

The data used to categorize each county or equivalent area is available in the Downloads section associated with the publication of the proposed rule at: <https://go.cms.gov/2KVwV8F>. In addition, an Excel file containing the rural county or equivalent area names, their FIPS state and county codes, and their designation into one of the three rural add-on categories is available for download.

h. Payments for High-Cost Outliers under the HH PPS

The fixed dollar loss (FDL) ratio and the loss-sharing ratio is selected so that the estimated total outlier payments do not exceed a 2.5 percent aggregate level. The current FDL ratio is 0.55.

CMS will change the FDL to 0.51 with a loss-sharing ratio of 0.80.

Bottom line is CMS has paid less than 2.5 in outlier payments in 2018.

3. Implementation of the Patient-Driven Groupings Model (PDGM) for CY 2020

The **BBA 2018** requires the Secretary to apply a 30-day unit of service for purposes of implementing the HH PPS, effective Jan. 1, 2020. CMS says the change will require provider education and training, updating and revising relevant manuals, and changing claims processing systems.

The PDGM would not use the number of therapy visits in determining payment. CMS notes that “the change from the current case-mix adjustment methodology for the HH PPS, which relies heavily on therapy thresholds as a major determinant for payment and thus provides a higher payment for a higher volume of therapy provided, to the PDGM would remove the financial incentive to overprovide therapy in order to receive a higher payment.”

Comment

This aspect of the rule is quite detailed in explaining the construct and measures used in developing the PDGM. Those involved in coding, etc. need to review the material in detail to fully comprehend the changes being made. Following are various “Final Decision” sections. The page numbers are based on the Adobe page counts in the display copy of the regulation.

Final Decisions

Page 118 *Thirty (30) Day Payment Cycles*

CMS is finalizing the change in the unit of payment from 60 days to 30 days, effective for 30-day periods of care that start on or after Jan. 1, 2020, as proposed, and in accordance with the provisions in the BBA of 2018.

Page 127 *Cost-per-Minute*

CMS is finalizing its proposal to adopt a Cost-per-Minute plus Non-Routine Supplies (CPM + NRS) approach in estimating resource use, which uses information from HHA Medicare cost reports.

Page 161 *Behavioral Assumptions*

CMS is finalizing three behavioral assumptions – Clinical Group Coding; Comorbidity Coding; and LUPA threshold -- in calculating a 30-day budget-neutral payment amount. CMS will update the CY 2020 30-day budget-neutral payment amount in the CY 2020 proposed rule using the most recent data available.

Page 167 *Split Billing Percentage*

CMS is finalizing its split-percentage proposal. This means that newly-enrolled HHAs, that is HHAs certified for participation in Medicare effective on or after Jan. 1, 2019, would not receive Request for Anticipated Payment (RAP) payments beginning in CY 2020. HHAs that are certified for participation in Medicare effective on or after Jan. 1, 2019, would still be required to submit a “no pay” RAP at the beginning of care in order to establish the home health period of care, as well as every 30-days thereafter.

Existing HHAs, meaning those HHAs that are certified for participation in Medicare effective prior to Jan. 1, 2019, will continue to receive RAP payments upon implementation of the PDGM in CY 2020. For split-percentage payments to be made, existing HHAs would have to submit a RAP at the beginning of each 30-day period of care and a final claim would be submitted at the end of each 30-day period of care. For the first 30-day period of care, the split percentage payment would be 60/40 and all subsequent 30-day periods of care would be a split percentage payment of 50/50.

Page 177 *Early or Late Classifications*

CMS will classify 30-day periods of care under the PDGM as “early” or “late” depending on when they occur within a sequence of 30-day periods. The first 30-day period would be classified as early and all subsequent 30-day periods in the sequence (second or later) would be classified as late and 30-day periods of care cannot be considered early unless there is a gap of more than 60 days between the end of one period and the start of another.

Page 196 *Institutional or Community Admissions*

CMS will establish two admission source categories for grouping 30-day periods of care under the PDGM— institutional and community—as determined by the healthcare setting utilized in the 14 days prior to home health admission. Thirty-day periods for beneficiaries with any inpatient acute care hospitalizations, inpatient psychiatric facility (IPF) stays, skilled nursing facility (SNF) stays, inpatient rehabilitation facility (IRF) stays, or long term care hospital (LTCH) stays within the 14 days prior to a home health admission will be designated as institutional admissions.

All other 30-day periods will be designated as community admissions. For the purposes of a RAP, CMS would only adjust the final home health claim submitted for source of admission. For example, if a RAP

for a community admission was submitted and paid, and then an acute or PAC Medicare claim was submitted for that patient before the final home health claim was submitted, CMS would not adjust the RAP and would only adjust the final home health claim so that it reflected an institutional admission. Additionally, HHAs would only indicate admission source occurrence codes on the final claim and not on any RAPs submitted.

Page 215 **Clinical Care Groups**

CMS is finalizing, with modification, its approach to grouping 30-day periods of care into clinical groups that represent the primary reason for home health care. CMS is finalizing twelve clinical groups, as shown below, which capture the most common primary reasons for home health care. The additional groups are a result of dividing the MMTA clinical group into 7 sub-groups. CMS notes that although it is categorizing patients into twelve groups according to the principal diagnosis, these groups do not reflect all the care being provided to the home health patient during a 30-day period of care. Home health care remains a multidisciplinary benefit.

Final Clinical Groups Used in the PDGM

| Clinical Groups | The Primary Reason for the Home Health Encounter is to Provide: |
|---|--|
| Musculoskeletal Rehabilitation | Therapy (physical, occupational or speech) for a musculoskeletal condition |
| Neuro/Stroke Rehabilitation | Therapy (physical, occupational or speech) for a neurological condition or stroke |
| Wounds – Post-Op Wound Aftercare and Skin/Non-Surgical Wound Care | Assessment, treatment & evaluation of a surgical wound(s); assessment, treatment & evaluation of non-surgical wounds, ulcers, burns, and other lesions |
| Behavioral Health Care | Assessment, treatment & evaluation of psychiatric conditions |
| Complex Nursing Interventions | Assessment, treatment & evaluation of complex medical & surgical conditions including IV, TPN, enteral nutrition, ventilator, and ostomies |
| Medication Management, Teaching and Assessment (MMTA) | |
| MMTA –Surgical Aftercare | Assessment, evaluation, teaching, and medication management for surgical aftercare |
| MMTA – Cardiac/Circulatory | Assessment, evaluation, teaching, and medication management for cardiac or other circulatory related conditions |
| MMTA – Endocrine | Assessment, evaluation, teaching, and medication management for endocrine related conditions |
| MMTA – GI/GU | Assessment, evaluation, teaching, and medication management for gastrointestinal or genitourinary related conditions |
| MMTA – Infectious Disease/Neoplasms/Blood-forming Diseases | Assessment, evaluation, teaching, and medication management for conditions related to infectious diseases, neoplasms, and blood-forming diseases |
| MMTA –Respiratory | Assessment, evaluation, teaching, and medication management for respiratory related conditions |
| MMTA – Other | Assessment, evaluation, teaching, and medication management for a variety of medical and surgical conditions not classified in one of the previously listed groups |

Page 244 **Functional Impairment Levels and Corresponding OASIS Items**

CMS says that after review of public comments, it is finalizing the use of OASIS items: M1800, M1810, M1820, M1830, M1840, M1850, M1860 and M1033 for the functional impairment level case-mix adjustment under the PDGM.

Page 258 **Comorbidity Adjustment**

CMS is finalizing the comorbidity adjustment as part of the overall case mix in the PDGM. To summarize, this includes the home health specific list of comorbidity subgroups and comorbidity subgroup interactions. One of the three mutually exclusive categories of comorbidity adjustment will be applied to

each period: No Comorbidity Adjustment, Low Comorbidity Adjustment, and High Comorbidity adjustment.

Page 263 **Change in the Low-Utilization Payment Adjustment (LUPA) Threshold**

CMS is finalizing its proposal to vary the LUPA threshold for each 30-day period of care depending on the PDGM payment group to which it is assigned.

The LUPA thresholds for the PDGM payment groups with the corresponding HIPPS codes based on CY 2017 home health data are listed in the rule’s Table 32 (beginning on page 264 of the rule’s display copy).

Page 288 **HH PPS Case-Mix Weights under the PDGM**

CMS is finalizing the PDGM, with the modifications, effective for 30-day periods of care that start on or after Jan. 1, 2020.

This new methodology results in 432 unique case-mix groups. These 432 unique case-mix payment groups are called Home Health Resource Groups (HHRGs).

Case-Mix Weights for Each HHRG Payment Group

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 1AA11 | MMTA - Other - Low | Early - Community | 0 | 0.9939 |
| 1AA21 | MMTA - Other - Low | Early - Community | 1 | 1.0536 |
| 1AA31 | MMTA - Other - Low | Early - Community | 2 | 1.1786 |
| 1AB11 | MMTA - Other - Medium | Early - Community | 0 | 1.1339 |
| 1AB21 | MMTA - Other - Medium | Early - Community | 1 | 1.1936 |
| 1AB31 | MMTA - Other - Medium | Early - Community | 2 | 1.3186 |
| 1AC11 | MMTA - Other - High | Early - Community | 0 | 1.2595 |
| 1AC21 | MMTA - Other - High | Early - Community | 1 | 1.3191 |
| 1AC31 | MMTA - Other - High | Early - Community | 2 | 1.4442 |
| 1BA11 | Neuro - Low | Early - Community | 0 | 1.1862 |
| 1BA21 | Neuro - Low | Early - Community | 1 | 1.2458 |
| 1BA31 | Neuro - Low | Early - Community | 2 | 1.3708 |
| 1BB11 | Neuro - Medium | Early - Community | 0 | 1.3571 |
| 1BB21 | Neuro - Medium | Early - Community | 1 | 1.4167 |
| 1BB31 | Neuro - Medium | Early - Community | 2 | 1.5418 |
| 1BC11 | Neuro - High | Early - Community | 0 | 1.4562 |
| 1BC21 | Neuro - High | Early - Community | 1 | 1.5158 |
| 1BC31 | Neuro - High | Early - Community | 2 | 1.6408 |
| 1CA11 | Wound - Low | Early - Community | 0 | 1.2199 |
| 1CA21 | Wound - Low | Early - Community | 1 | 1.2795 |
| 1CA31 | Wound - Low | Early - Community | 2 | 1.4046 |
| 1CB11 | Wound - Medium | Early - Community | 0 | 1.3724 |
| 1CB21 | Wound - Medium | Early - Community | 1 | 1.4321 |
| 1CB31 | Wound - Medium | Early - Community | 2 | 1.5571 |
| 1CC11 | Wound - High | Early - Community | 0 | 1.4919 |
| 1CC21 | Wound - High | Early - Community | 1 | 1.5516 |
| 1CC31 | Wound - High | Early - Community | 2 | 1.6766 |
| 1DA11 | Complex - Low | Early - Community | 0 | 0.9520 |
| 1DA21 | Complex - Low | Early - Community | 1 | 1.0117 |
| 1DA31 | Complex - Low | Early - Community | 2 | 1.1367 |
| 1DB11 | Complex - Medium | Early - Community | 0 | 1.1588 |
| 1DB21 | Complex - Medium | Early - Community | 1 | 1.2185 |

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 1DB31 | Complex - Medium | Early - Community | 2 | 1.3435 |
| 1DC11 | Complex - High | Early - Community | 0 | 1.1966 |
| 1DC21 | Complex - High | Early - Community | 1 | 1.2563 |
| 1DC31 | Complex - High | Early - Community | 2 | 1.3813 |
| 1EA11 | MS Rehab - Low | Early - Community | 0 | 1.0751 |
| 1EA21 | MS Rehab - Low | Early - Community | 1 | 1.1348 |
| 1EA31 | MS Rehab - Low | Early - Community | 2 | 1.2598 |
| 1EB11 | MS Rehab - Medium | Early - Community | 0 | 1.2025 |
| 1EB21 | MS Rehab - Medium | Early - Community | 1 | 1.2622 |
| 1EB31 | MS Rehab - Medium | Early - Community | 2 | 1.3872 |
| 1EC11 | MS Rehab - High | Early - Community | 0 | 1.3456 |
| 1EC21 | MS Rehab - High | Early - Community | 1 | 1.4053 |
| 1EC31 | MS Rehab - High | Early - Community | 2 | 1.5303 |
| 1FA11 | Behavioral Health - Low | Early - Community | 0 | 0.9056 |
| 1FA21 | Behavioral Health - Low | Early - Community | 1 | 0.9652 |
| 1FA31 | Behavioral Health - Low | Early - Community | 2 | 1.0902 |
| 1FB11 | Behavioral Health - Medium | Early - Community | 0 | 1.0832 |
| 1FB21 | Behavioral Health - Medium | Early - Community | 1 | 1.1428 |
| 1FB31 | Behavioral Health - Medium | Early - Community | 2 | 1.2678 |
| 1FC11 | Behavioral Health - High | Early - Community | 0 | 1.1715 |
| 1FC21 | Behavioral Health - High | Early - Community | 1 | 1.2311 |
| 1FC31 | Behavioral Health - High | Early - Community | 2 | 1.3562 |
| 1GA11 | MMTA - Surgical Aftercare - Low | Early - Community | 0 | 0.8826 |
| 1GA21 | MMTA - Surgical Aftercare - Low | Early - Community | 1 | 0.9422 |
| 1GA31 | MMTA - Surgical Aftercare - Low | Early - Community | 2 | 1.0672 |
| 1GB11 | MMTA - Surgical Aftercare - Medium | Early - Community | 0 | 1.0470 |
| 1GB21 | MMTA - Surgical Aftercare - Medium | Early - Community | 1 | 1.1066 |
| 1GB31 | MMTA - Surgical Aftercare - Medium | Early - Community | 2 | 1.2316 |
| 1GC11 | MMTA - Surgical Aftercare - High | Early - Community | 0 | 1.2029 |
| 1GC21 | MMTA - Surgical Aftercare - High | Early - Community | 1 | 1.2625 |
| 1GC31 | MMTA - Surgical Aftercare - High | Early - Community | 2 | 1.3875 |
| 1HA11 | MMTA - Cardiac - Low | Early - Community | 0 | 0.9722 |
| 1HA21 | MMTA - Cardiac - Low | Early - Community | 1 | 1.0319 |
| 1HA31 | MMTA - Cardiac - Low | Early - Community | 2 | 1.1569 |
| 1HB11 | MMTA - Cardiac - Medium | Early - Community | 0 | 1.1256 |
| 1HB21 | MMTA - Cardiac - Medium | Early - Community | 1 | 1.1853 |
| 1HB31 | MMTA - Cardiac - Medium | Early - Community | 2 | 1.3103 |
| 1HC11 | MMTA - Cardiac - High | Early - Community | 0 | 1.2403 |
| 1HC21 | MMTA - Cardiac - High | Early - Community | 1 | 1.2999 |
| 1HC31 | MMTA - Cardiac - High | Early - Community | 2 | 1.4249 |
| 1IA11 | MMTA - Endocrine - Low | Early - Community | 0 | 1.0913 |
| 1IA21 | MMTA - Endocrine - Low | Early - Community | 1 | 1.1509 |
| 1IA31 | MMTA - Endocrine - Low | Early - Community | 2 | 1.2759 |
| 1IB11 | MMTA - Endocrine - Medium | Early - Community | 0 | 1.2561 |
| 1IB21 | MMTA - Endocrine - Medium | Early - Community | 1 | 1.3158 |
| 1IB31 | MMTA - Endocrine - Medium | Early - Community | 2 | 1.4408 |
| 1IC11 | MMTA - Endocrine - High | Early - Community | 0 | 1.3783 |
| 1IC21 | MMTA - Endocrine - High | Early - Community | 1 | 1.4379 |
| 1IC31 | MMTA - Endocrine - High | Early - Community | 2 | 1.5630 |
| 1JA11 | MMTA - GI/GU - Low | Early - Community | 0 | 0.9318 |
| 1JA21 | MMTA - GI/GU - Low | Early - Community | 1 | 0.9914 |
| 1JA31 | MMTA - GI/GU - Low | Early - Community | 2 | 1.1165 |
| 1JB11 | MMTA - GI/GU - Medium | Early - Community | 0 | 1.0954 |

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 1JB21 | MMTA - GI/GU - Medium | Early - Community | 1 | 1.1550 |
| 1JB31 | MMTA - GI/GU - Medium | Early - Community | 2 | 1.2800 |
| 1JC11 | MMTA - GI/GU - High | Early - Community | 0 | 1.1891 |
| 1JC21 | MMTA - GI/GU - High | Early - Community | 1 | 1.2487 |
| 1JC31 | MMTA - GI/GU - High | Early - Community | 2 | 1.3738 |
| 1KA11 | MMTA - Infectious - Low | Early - Community | 0 | 0.9642 |
| 1KA21 | MMTA - Infectious - Low | Early - Community | 1 | 1.0239 |
| 1KA31 | MMTA - Infectious - Low | Early - Community | 2 | 1.1489 |
| 1KB11 | MMTA - Infectious - Medium | Early - Community | 0 | 1.0994 |
| 1KB21 | MMTA - Infectious - Medium | Early - Community | 1 | 1.1590 |
| 1KB31 | MMTA - Infectious - Medium | Early - Community | 2 | 1.2841 |
| 1KC11 | MMTA - Infectious - High | Early - Community | 0 | 1.2107 |
| 1KC21 | MMTA - Infectious - High | Early - Community | 1 | 1.2703 |
| 1KC31 | MMTA - Infectious - High | Early - Community | 2 | 1.3954 |
| 1LA11 | MMTA - Respiratory - Low | Early - Community | 0 | 0.9491 |
| 1LA21 | MMTA - Respiratory - Low | Early - Community | 1 | 1.0087 |
| 1LA31 | MMTA - Respiratory - Low | Early - Community | 2 | 1.1338 |
| 1LB11 | MMTA - Respiratory - Medium | Early - Community | 0 | 1.0930 |
| 1LB21 | MMTA - Respiratory - Medium | Early - Community | 1 | 1.1526 |
| 1LB31 | MMTA - Respiratory - Medium | Early - Community | 2 | 1.2777 |
| 1LC11 | MMTA - Respiratory - High | Early - Community | 0 | 1.2021 |
| 1LC21 | MMTA - Respiratory - High | Early - Community | 1 | 1.2617 |
| 1LC31 | MMTA - Respiratory - High | Early - Community | 2 | 1.3867 |
| 2AA11 | MMTA - Other - Low | Early - Institutional | 0 | 1.1759 |
| 2AA21 | MMTA - Other - Low | Early - Institutional | 1 | 1.2355 |
| 2AA31 | MMTA - Other - Low | Early - Institutional | 2 | 1.3606 |
| 2AB11 | MMTA - Other - Medium | Early - Institutional | 0 | 1.3159 |
| 2AB21 | MMTA - Other - Medium | Early - Institutional | 1 | 1.3755 |
| 2AB31 | MMTA - Other - Medium | Early - Institutional | 2 | 1.5006 |
| 2AC11 | MMTA - Other - High | Early - Institutional | 0 | 1.4415 |
| 2AC21 | MMTA - Other - High | Early - Institutional | 1 | 1.5011 |
| 2AC31 | MMTA - Other - High | Early - Institutional | 2 | 1.6261 |
| 2BA11 | Neuro - Low | Early - Institutional | 0 | 1.3681 |
| 2BA21 | Neuro - Low | Early - Institutional | 1 | 1.4278 |
| 2BA31 | Neuro - Low | Early - Institutional | 2 | 1.5528 |
| 2BB11 | Neuro - Medium | Early - Institutional | 0 | 1.5391 |
| 2BB21 | Neuro - Medium | Early - Institutional | 1 | 1.5987 |
| 2BB31 | Neuro - Medium | Early - Institutional | 2 | 1.7237 |
| 2BC11 | Neuro - High | Early - Institutional | 0 | 1.6381 |
| 2BC21 | Neuro - High | Early - Institutional | 1 | 1.6978 |
| 2BC31 | Neuro - High | Early - Institutional | 2 | 1.8228 |
| 2CA11 | Wound - Low | Early - Institutional | 0 | 1.4019 |
| 2CA21 | Wound - Low | Early - Institutional | 1 | 1.4615 |
| 2CA31 | Wound - Low | Early - Institutional | 2 | 1.5865 |
| 2CB11 | Wound - Medium | Early - Institutional | 0 | 1.5544 |
| 2CB21 | Wound - Medium | Early - Institutional | 1 | 1.6140 |
| 2CB31 | Wound - Medium | Early - Institutional | 2 | 1.7391 |
| 2CC11 | Wound - High | Early - Institutional | 0 | 1.6739 |
| 2CC21 | Wound - High | Early - Institutional | 1 | 1.7335 |
| 2CC31 | Wound - High | Early - Institutional | 2 | 1.8586 |
| 2DA11 | Complex - Low | Early - Institutional | 0 | 1.1340 |
| 2DA21 | Complex - Low | Early - Institutional | 1 | 1.1936 |
| 2DA31 | Complex - Low | Early - Institutional | 2 | 1.3187 |
| 2DB11 | Complex - Medium | Early - Institutional | 0 | 1.3408 |

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 2DB21 | Complex - Medium | Early - Institutional | 1 | 1.4004 |
| 2DB31 | Complex - Medium | Early - Institutional | 2 | 1.5255 |
| 2DC11 | Complex - High | Early - Institutional | 0 | 1.3786 |
| 2DC21 | Complex - High | Early - Institutional | 1 | 1.4382 |
| 2DC31 | Complex - High | Early - Institutional | 2 | 1.5633 |
| 2EA11 | MS Rehab - Low | Early - Institutional | 0 | 1.2571 |
| 2EA21 | MS Rehab - Low | Early - Institutional | 1 | 1.3167 |
| 2EA31 | MS Rehab - Low | Early - Institutional | 2 | 1.4418 |
| 2EB11 | MS Rehab - Medium | Early - Institutional | 0 | 1.3845 |
| 2EB21 | MS Rehab - Medium | Early - Institutional | 1 | 1.4441 |
| 2EB31 | MS Rehab - Medium | Early - Institutional | 2 | 1.5692 |
| 2EC11 | MS Rehab - High | Early - Institutional | 0 | 1.5276 |
| 2EC21 | MS Rehab - High | Early - Institutional | 1 | 1.5872 |
| 2EC31 | MS Rehab - High | Early - Institutional | 2 | 1.7123 |
| 2FA11 | Behavioral Health - Low | Early - Institutional | 0 | 1.0875 |
| 2FA21 | Behavioral Health - Low | Early - Institutional | 1 | 1.1472 |
| 2FA31 | Behavioral Health - Low | Early - Institutional | 2 | 1.2722 |
| 2FB11 | Behavioral Health - Medium | Early - Institutional | 0 | 1.2651 |
| 2FB21 | Behavioral Health - Medium | Early - Institutional | 1 | 1.3247 |
| 2FB31 | Behavioral Health - Medium | Early - Institutional | 2 | 1.4498 |
| 2FC11 | Behavioral Health - High | Early - Institutional | 0 | 1.3535 |
| 2FC21 | Behavioral Health - High | Early - Institutional | 1 | 1.4131 |
| 2FC31 | Behavioral Health - High | Early - Institutional | 2 | 1.5381 |
| 2GA11 | MMTA - Surgical Aftercare - Low | Early - Institutional | 0 | 1.0645 |
| 2GA21 | MMTA - Surgical Aftercare - Low | Early - Institutional | 1 | 1.1241 |
| 2GA31 | MMTA - Surgical Aftercare - Low | Early - Institutional | 2 | 1.2492 |
| 2GB11 | MMTA - Surgical Aftercare - Medium | Early - Institutional | 0 | 1.2289 |
| 2GB21 | MMTA - Surgical Aftercare - Medium | Early - Institutional | 1 | 1.2886 |
| 2GB31 | MMTA - Surgical Aftercare - Medium | Early - Institutional | 2 | 1.4136 |
| 2GC11 | MMTA - Surgical Aftercare - High | Early - Institutional | 0 | 1.3848 |
| 2GC21 | MMTA - Surgical Aftercare - High | Early - Institutional | 1 | 1.4444 |
| 2GC31 | MMTA - Surgical Aftercare - High | Early - Institutional | 2 | 1.5695 |
| 2HA11 | MMTA - Cardiac - Low | Early - Institutional | 0 | 1.1542 |
| 2HA21 | MMTA - Cardiac - Low | Early - Institutional | 1 | 1.2138 |
| 2HA31 | MMTA - Cardiac - Low | Early - Institutional | 2 | 1.3389 |
| 2HB11 | MMTA - Cardiac - Medium | Early - Institutional | 0 | 1.3076 |
| 2HB21 | MMTA - Cardiac - Medium | Early - Institutional | 1 | 1.3672 |
| 2HB31 | MMTA - Cardiac - Medium | Early - Institutional | 2 | 1.4923 |
| 2HC11 | MMTA - Cardiac - High | Early - Institutional | 0 | 1.4222 |
| 2HC21 | MMTA - Cardiac - High | Early - Institutional | 1 | 1.4818 |
| 2HC31 | MMTA - Cardiac - High | Early - Institutional | 2 | 1.6069 |
| 2IA11 | MMTA - Endocrine - Low | Early - Institutional | 0 | 1.2732 |
| 2IA21 | MMTA - Endocrine - Low | Early - Institutional | 1 | 1.3329 |
| 2IA31 | MMTA - Endocrine - Low | Early - Institutional | 2 | 1.4579 |
| 2IB11 | MMTA - Endocrine - Medium | Early - Institutional | 0 | 1.4381 |
| 2IB21 | MMTA - Endocrine - Medium | Early - Institutional | 1 | 1.4977 |
| 2IB31 | MMTA - Endocrine - Medium | Early - Institutional | 2 | 1.6228 |
| 2IC11 | MMTA - Endocrine - High | Early - Institutional | 0 | 1.5603 |
| 2IC21 | MMTA - Endocrine - High | Early - Institutional | 1 | 1.6199 |
| 2IC31 | MMTA - Endocrine - High | Early - Institutional | 2 | 1.7449 |
| 2JA11 | MMTA - GI/GU - Low | Early - Institutional | 0 | 1.1138 |

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 2JA21 | MMTA - GI/GU - Low | Early - Institutional | 1 | 1.1734 |
| 2JA31 | MMTA - GI/GU - Low | Early - Institutional | 2 | 1.2985 |
| 2JB11 | MMTA - GI/GU - Medium | Early - Institutional | 0 | 1.2773 |
| 2JB21 | MMTA - GI/GU - Medium | Early - Institutional | 1 | 1.3370 |
| 2JB31 | MMTA - GI/GU - Medium | Early - Institutional | 2 | 1.4620 |
| 2JC11 | MMTA - GI/GU - High | Early - Institutional | 0 | 1.3711 |
| 2JC21 | MMTA - GI/GU - High | Early - Institutional | 1 | 1.4307 |
| 2JC31 | MMTA - GI/GU - High | Early - Institutional | 2 | 1.5558 |
| 2KA11 | MMTA - Infectious - Low | Early - Institutional | 0 | 1.1462 |
| 2KA21 | MMTA - Infectious - Low | Early - Institutional | 1 | 1.2058 |
| 2KA31 | MMTA - Infectious - Low | Early - Institutional | 2 | 1.3309 |
| 2KB11 | MMTA - Infectious - Medium | Early - Institutional | 0 | 1.2814 |
| 2KB21 | MMTA - Infectious - Medium | Early - Institutional | 1 | 1.3410 |
| 2KB31 | MMTA - Infectious - Medium | Early - Institutional | 2 | 1.4660 |
| 2KC11 | MMTA - Infectious - High | Early - Institutional | 0 | 1.3927 |
| 2KC21 | MMTA - Infectious - High | Early - Institutional | 1 | 1.4523 |
| 2KC31 | MMTA - Infectious - High | Early - Institutional | 2 | 1.5773 |
| 2LA11 | MMTA - Respiratory - Low | Early - Institutional | 0 | 1.1311 |
| 2LA21 | MMTA - Respiratory - Low | Early - Institutional | 1 | 1.1907 |
| 2LA31 | MMTA - Respiratory - Low | Early - Institutional | 2 | 1.3157 |
| 2LB11 | MMTA - Respiratory - Medium | Early - Institutional | 0 | 1.2750 |
| 2LB21 | MMTA - Respiratory - Medium | Early - Institutional | 1 | 1.3346 |
| 2LB31 | MMTA - Respiratory - Medium | Early - Institutional | 2 | 1.4596 |
| 2LC11 | MMTA - Respiratory - High | Early - Institutional | 0 | 1.3840 |
| 2LC21 | MMTA - Respiratory - High | Early - Institutional | 1 | 1.4436 |
| 2LC31 | MMTA - Respiratory - High | Early - Institutional | 2 | 1.5687 |
| 3AA11 | MMTA - Other - Low | Late - Community | 0 | 0.5898 |
| 3AA21 | MMTA - Other - Low | Late - Community | 1 | 0.6495 |
| 3AA31 | MMTA - Other - Low | Late - Community | 2 | 0.7745 |
| 3AB11 | MMTA - Other - Medium | Late - Community | 0 | 0.7298 |
| 3AB21 | MMTA - Other - Medium | Late - Community | 1 | 0.7894 |
| 3AB31 | MMTA - Other - Medium | Late - Community | 2 | 0.9145 |
| 3AC11 | MMTA - Other - High | Late - Community | 0 | 0.8554 |
| 3AC21 | MMTA - Other - High | Late - Community | 1 | 0.9150 |
| 3AC31 | MMTA - Other - High | Late - Community | 2 | 1.0401 |
| 3BA11 | Neuro - Low | Late - Community | 0 | 0.7821 |
| 3BA21 | Neuro - Low | Late - Community | 1 | 0.8417 |
| 3BA31 | Neuro - Low | Late - Community | 2 | 0.9667 |
| 3BB11 | Neuro - Medium | Late - Community | 0 | 0.9530 |
| 3BB21 | Neuro - Medium | Late - Community | 1 | 1.0126 |
| 3BB31 | Neuro - Medium | Late - Community | 2 | 1.1377 |
| 3BC11 | Neuro - High | Late - Community | 0 | 1.0520 |
| 3BC21 | Neuro - High | Late - Community | 1 | 1.1117 |
| 3BC31 | Neuro - High | Late - Community | 2 | 1.2367 |
| 3CA11 | Wound - Low | Late - Community | 0 | 0.8158 |
| 3CA21 | Wound - Low | Late - Community | 1 | 0.8754 |
| 3CA31 | Wound - Low | Late - Community | 2 | 1.0005 |
| 3CB11 | Wound - Medium | Late - Community | 0 | 0.9683 |
| 3CB21 | Wound - Medium | Late - Community | 1 | 1.0279 |
| 3CB31 | Wound - Medium | Late - Community | 2 | 1.1530 |
| 3CC11 | Wound - High | Late - Community | 0 | 1.0878 |
| 3CC21 | Wound - High | Late - Community | 1 | 1.1475 |
| 3CC31 | Wound - High | Late - Community | 2 | 1.2725 |
| 3DA11 | Complex - Low | Late - Community | 0 | 0.5479 |

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 3DA21 | Complex - Low | Late - Community | 1 | 0.6076 |
| 3DA31 | Complex - Low | Late - Community | 2 | 0.7326 |
| 3DB11 | Complex - Medium | Late - Community | 0 | 0.7547 |
| 3DB21 | Complex - Medium | Late - Community | 1 | 0.8143 |
| 3DB31 | Complex - Medium | Late - Community | 2 | 0.9394 |
| 3DC11 | Complex - High | Late - Community | 0 | 0.7925 |
| 3DC21 | Complex - High | Late - Community | 1 | 0.8522 |
| 3DC31 | Complex - High | Late - Community | 2 | 0.9772 |
| 3EA11 | MS Rehab - Low | Late - Community | 0 | 0.6710 |
| 3EA21 | MS Rehab - Low | Late - Community | 1 | 0.7307 |
| 3EA31 | MS Rehab - Low | Late - Community | 2 | 0.8557 |
| 3EB11 | MS Rehab - Medium | Late - Community | 0 | 0.7984 |
| 3EB21 | MS Rehab - Medium | Late - Community | 1 | 0.8581 |
| 3EB31 | MS Rehab - Medium | Late - Community | 2 | 0.9831 |
| 3EC11 | MS Rehab - High | Late - Community | 0 | 0.9415 |
| 3EC21 | MS Rehab - High | Late - Community | 1 | 1.0012 |
| 3EC31 | MS Rehab - High | Late - Community | 2 | 1.1262 |
| 3FA11 | Behavioral Health - Low | Late - Community | 0 | 0.5015 |
| 3FA21 | Behavioral Health - Low | Late - Community | 1 | 0.5611 |
| 3FA31 | Behavioral Health - Low | Late - Community | 2 | 0.6861 |
| 3FB11 | Behavioral Health - Medium | Late - Community | 0 | 0.6790 |
| 3FB21 | Behavioral Health - Medium | Late - Community | 1 | 0.7387 |
| 3FB31 | Behavioral Health - Medium | Late - Community | 2 | 0.8637 |
| 3FC11 | Behavioral Health - High | Late - Community | 0 | 0.7674 |
| 3FC21 | Behavioral Health - High | Late - Community | 1 | 0.8270 |
| 3FC31 | Behavioral Health - High | Late - Community | 2 | 0.9521 |
| 3GA11 | MMTA - Surgical Aftercare - Low | Late - Community | 0 | 0.4784 |
| 3GA21 | MMTA - Surgical Aftercare - Low | Late - Community | 1 | 0.5381 |
| 3GA31 | MMTA - Surgical Aftercare - Low | Late - Community | 2 | 0.6631 |
| 3GB11 | MMTA - Surgical Aftercare - Medium | Late - Community | 0 | 0.6429 |
| 3GB21 | MMTA - Surgical Aftercare - Medium | Late - Community | 1 | 0.7025 |
| 3GB31 | MMTA - Surgical Aftercare - Medium | Late - Community | 2 | 0.8275 |
| 3GC11 | MMTA - Surgical Aftercare - High | Late - Community | 0 | 0.7987 |
| 3GC21 | MMTA - Surgical Aftercare - High | Late - Community | 1 | 0.8584 |
| 3GC31 | MMTA - Surgical Aftercare - High | Late - Community | 2 | 0.9834 |
| 3HA11 | MMTA - Cardiac - Low | Late - Community | 0 | 0.5681 |
| 3HA21 | MMTA - Cardiac - Low | Late - Community | 1 | 0.6277 |
| 3HA31 | MMTA - Cardiac - Low | Late - Community | 2 | 0.7528 |
| 3HB11 | MMTA - Cardiac - Medium | Late - Community | 0 | 0.7215 |
| 3HB21 | MMTA - Cardiac - Medium | Late - Community | 1 | 0.7812 |
| 3HB31 | MMTA - Cardiac - Medium | Late - Community | 2 | 0.9062 |
| 3HC11 | MMTA - Cardiac - High | Late - Community | 0 | 0.8361 |
| 3HC21 | MMTA - Cardiac - High | Late - Community | 1 | 0.8958 |
| 3HC31 | MMTA - Cardiac - High | Late - Community | 2 | 1.0208 |
| 3IA11 | MMTA - Endocrine - Low | Late - Community | 0 | 0.6871 |
| 3IA21 | MMTA - Endocrine - Low | Late - Community | 1 | 0.7468 |
| 3IA31 | MMTA - Endocrine - Low | Late - Community | 2 | 0.8718 |
| 3IB11 | MMTA - Endocrine - Medium | Late - Community | 0 | 0.8520 |
| 3IB21 | MMTA - Endocrine - Medium | Late - Community | 1 | 0.9116 |
| 3IB31 | MMTA - Endocrine - Medium | Late - Community | 2 | 1.0367 |
| 3IC11 | MMTA - Endocrine - High | Late - Community | 0 | 0.9742 |

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 3IC21 | MMTA - Endocrine - High | Late - Community | 1 | 1.0338 |
| 3IC31 | MMTA - Endocrine - High | Late - Community | 2 | 1.1588 |
| 3JA11 | MMTA - GI/GU - Low | Late - Community | 0 | 0.5277 |
| 3JA21 | MMTA - GI/GU - Low | Late - Community | 1 | 0.5873 |
| 3JA31 | MMTA - GI/GU - Low | Late - Community | 2 | 0.7124 |
| 3JB11 | MMTA - GI/GU - Medium | Late - Community | 0 | 0.6913 |
| 3JB21 | MMTA - GI/GU - Medium | Late - Community | 1 | 0.7509 |
| 3JB31 | MMTA - GI/GU - Medium | Late - Community | 2 | 0.8759 |
| 3JC11 | MMTA - GI/GU - High | Late - Community | 0 | 0.7850 |
| 3JC21 | MMTA - GI/GU - High | Late - Community | 1 | 0.8446 |
| 3JC31 | MMTA - GI/GU - High | Late - Community | 2 | 0.9697 |
| 3KA11 | MMTA - Infectious - Low | Late - Community | 0 | 0.5601 |
| 3KA21 | MMTA - Infectious - Low | Late - Community | 1 | 0.6198 |
| 3KA31 | MMTA - Infectious - Low | Late - Community | 2 | 0.7448 |
| 3KB11 | MMTA - Infectious - Medium | Late - Community | 0 | 0.6953 |
| 3KB21 | MMTA - Infectious - Medium | Late - Community | 1 | 0.7549 |
| 3KB31 | MMTA - Infectious - Medium | Late - Community | 2 | 0.8799 |
| 3KC11 | MMTA - Infectious - High | Late - Community | 0 | 0.8066 |
| 3KC21 | MMTA - Infectious - High | Late - Community | 1 | 0.8662 |
| 3KC31 | MMTA - Infectious - High | Late - Community | 2 | 0.9913 |
| 3LA11 | MMTA - Respiratory - Low | Late - Community | 0 | 0.5450 |
| 3LA21 | MMTA - Respiratory - Low | Late - Community | 1 | 0.6046 |
| 3LA31 | MMTA - Respiratory - Low | Late - Community | 2 | 0.7297 |
| 3LB11 | MMTA - Respiratory - Medium | Late - Community | 0 | 0.6889 |
| 3LB21 | MMTA - Respiratory - Medium | Late - Community | 1 | 0.7485 |
| 3LB31 | MMTA - Respiratory - Medium | Late - Community | 2 | 0.8735 |
| 3LC11 | MMTA - Respiratory - High | Late - Community | 0 | 0.7979 |
| 3LC21 | MMTA - Respiratory - High | Late - Community | 1 | 0.8576 |
| 3LC31 | MMTA - Respiratory - High | Late - Community | 2 | 0.9826 |
| 4AA11 | MMTA - Other - Low | Late - Institutional | 0 | 1.0367 |
| 4AA21 | MMTA - Other - Low | Late - Institutional | 1 | 1.0964 |
| 4AA31 | MMTA - Other - Low | Late - Institutional | 2 | 1.2214 |
| 4AB11 | MMTA - Other - Medium | Late - Institutional | 0 | 1.1767 |
| 4AB21 | MMTA - Other - Medium | Late - Institutional | 1 | 1.2364 |
| 4AB31 | MMTA - Other - Medium | Late - Institutional | 2 | 1.3614 |
| 4AC11 | MMTA - Other - High | Late - Institutional | 0 | 1.3023 |
| 4AC21 | MMTA - Other - High | Late - Institutional | 1 | 1.3619 |
| 4AC31 | MMTA - Other - High | Late - Institutional | 2 | 1.4870 |
| 4BA11 | Neuro - Low | Late - Institutional | 0 | 1.2290 |
| 4BA21 | Neuro - Low | Late - Institutional | 1 | 1.2886 |
| 4BA31 | Neuro - Low | Late - Institutional | 2 | 1.4136 |
| 4BB11 | Neuro - Medium | Late - Institutional | 0 | 1.3999 |
| 4BB21 | Neuro - Medium | Late - Institutional | 1 | 1.4595 |
| 4BB31 | Neuro - Medium | Late - Institutional | 2 | 1.5846 |
| 4BC11 | Neuro - High | Late - Institutional | 0 | 1.4990 |
| 4BC21 | Neuro - High | Late - Institutional | 1 | 1.5586 |
| 4BC31 | Neuro - High | Late - Institutional | 2 | 1.6836 |
| 4CA11 | Wound - Low | Late - Institutional | 0 | 1.2627 |
| 4CA21 | Wound - Low | Late - Institutional | 1 | 1.3223 |
| 4CA31 | Wound - Low | Late - Institutional | 2 | 1.4474 |
| 4CB11 | Wound - Medium | Late - Institutional | 0 | 1.4152 |
| 4CB21 | Wound - Medium | Late - Institutional | 1 | 1.4749 |
| 4CB31 | Wound - Medium | Late - Institutional | 2 | 1.5999 |
| 4CC11 | Wound - High | Late - Institutional | 0 | 1.5347 |

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 4CC21 | Wound - High | Late - Institutional | 1 | 1.5944 |
| 4CC31 | Wound - High | Late - Institutional | 2 | 1.7194 |
| 4DA11 | Complex - Low | Late - Institutional | 0 | 0.9948 |
| 4DA21 | Complex - Low | Late - Institutional | 1 | 1.0545 |
| 4DA31 | Complex - Low | Late - Institutional | 2 | 1.1795 |
| 4DB11 | Complex - Medium | Late - Institutional | 0 | 1.2016 |
| 4DB21 | Complex - Medium | Late - Institutional | 1 | 1.2613 |
| 4DB31 | Complex - Medium | Late - Institutional | 2 | 1.3863 |
| 4DC11 | Complex - High | Late - Institutional | 0 | 1.2395 |
| 4DC21 | Complex - High | Late - Institutional | 1 | 1.2991 |
| 4DC31 | Complex - High | Late - Institutional | 2 | 1.4241 |
| 4EA11 | MS Rehab - Low | Late - Institutional | 0 | 1.1179 |
| 4EA21 | MS Rehab - Low | Late - Institutional | 1 | 1.1776 |
| 4EA31 | MS Rehab - Low | Late - Institutional | 2 | 1.3026 |
| 4EB11 | MS Rehab - Medium | Late - Institutional | 0 | 1.2453 |
| 4EB21 | MS Rehab - Medium | Late - Institutional | 1 | 1.3050 |
| 4EB31 | MS Rehab - Medium | Late - Institutional | 2 | 1.4300 |
| 4EC11 | MS Rehab - High | Late - Institutional | 0 | 1.3884 |
| 4EC21 | MS Rehab - High | Late - Institutional | 1 | 1.4481 |
| 4EC31 | MS Rehab - High | Late - Institutional | 2 | 1.5731 |
| 4FA11 | Behavioral Health - Low | Late - Institutional | 0 | 0.9484 |
| 4FA21 | Behavioral Health - Low | Late - Institutional | 1 | 1.0080 |
| 4FA31 | Behavioral Health - Low | Late - Institutional | 2 | 1.1330 |
| 4FB11 | Behavioral Health - Medium | Late - Institutional | 0 | 1.1260 |
| 4FB21 | Behavioral Health - Medium | Late - Institutional | 1 | 1.1856 |
| 4FB31 | Behavioral Health - Medium | Late - Institutional | 2 | 1.3106 |
| 4FC11 | Behavioral Health - High | Late - Institutional | 0 | 1.2143 |
| 4FC21 | Behavioral Health - High | Late - Institutional | 1 | 1.2739 |
| 4FC31 | Behavioral Health - High | Late - Institutional | 2 | 1.3990 |
| 4GA11 | MMTA - Surgical Aftercare - Low | Late - Institutional | 0 | 0.9254 |
| 4GA21 | MMTA - Surgical Aftercare - Low | Late - Institutional | 1 | 0.9850 |
| 4GA31 | MMTA - Surgical Aftercare - Low | Late - Institutional | 2 | 1.1100 |
| 4GB11 | MMTA - Surgical Aftercare - Medium | Late - Institutional | 0 | 1.0898 |
| 4GB21 | MMTA - Surgical Aftercare - Medium | Late - Institutional | 1 | 1.1494 |
| 4GB31 | MMTA - Surgical Aftercare - Medium | Late - Institutional | 2 | 1.2744 |
| 4GC11 | MMTA - Surgical Aftercare - High | Late - Institutional | 0 | 1.2457 |
| 4GC21 | MMTA - Surgical Aftercare - High | Late - Institutional | 1 | 1.3053 |
| 4GC31 | MMTA - Surgical Aftercare - High | Late - Institutional | 2 | 1.4303 |
| 4HA11 | MMTA - Cardiac - Low | Late - Institutional | 0 | 1.0150 |
| 4HA21 | MMTA - Cardiac - Low | Late - Institutional | 1 | 1.0747 |
| 4HA31 | MMTA - Cardiac - Low | Late - Institutional | 2 | 1.1997 |
| 4HB11 | MMTA - Cardiac - Medium | Late - Institutional | 0 | 1.1684 |
| 4HB21 | MMTA - Cardiac - Medium | Late - Institutional | 1 | 1.2281 |
| 4HB31 | MMTA - Cardiac - Medium | Late - Institutional | 2 | 1.3531 |
| 4HC11 | MMTA - Cardiac - High | Late - Institutional | 0 | 1.2831 |
| 4HC21 | MMTA - Cardiac - High | Late - Institutional | 1 | 1.3427 |
| 4HC31 | MMTA - Cardiac - High | Late - Institutional | 2 | 1.4677 |
| 4IA11 | MMTA - Endocrine - Low | Late - Institutional | 0 | 1.1341 |
| 4IA21 | MMTA - Endocrine - Low | Late - Institutional | 1 | 1.1937 |
| 4IA31 | MMTA - Endocrine - Low | Late - Institutional | 2 | 1.3187 |
| 4IB11 | MMTA - Endocrine - Medium | Late - Institutional | 0 | 1.2989 |

| HIPPS | Clinical Group and Functional Level | Timing and Admission Source | Comorbidity Adjustment (0 = none, 1 = single comorbidity, 2 = interaction) | CY 2019 Weight |
|-------|-------------------------------------|-----------------------------|--|----------------|
| 4IB21 | MMTA - Endocrine - Medium | Late - Institutional | 1 | 1.3586 |
| 4IB31 | MMTA - Endocrine - Medium | Late - Institutional | 2 | 1.4836 |
| 4IC11 | MMTA - Endocrine - High | Late - Institutional | 0 | 1.4211 |
| 4IC21 | MMTA - Endocrine - High | Late - Institutional | 1 | 1.4807 |
| 4IC31 | MMTA - Endocrine - High | Late - Institutional | 2 | 1.6058 |
| 4JA11 | MMTA - GI/GU - Low | Late - Institutional | 0 | 0.9746 |
| 4JA21 | MMTA - GI/GU - Low | Late - Institutional | 1 | 1.0342 |
| 4JA31 | MMTA - GI/GU - Low | Late - Institutional | 2 | 1.1593 |
| 4JB11 | MMTA - GI/GU - Medium | Late - Institutional | 0 | 1.1382 |
| 4JB21 | MMTA - GI/GU - Medium | Late - Institutional | 1 | 1.1978 |
| 4JB31 | MMTA - GI/GU - Medium | Late - Institutional | 2 | 1.3228 |
| 4JC11 | MMTA - GI/GU - High | Late - Institutional | 0 | 1.2319 |
| 4JC21 | MMTA - GI/GU - High | Late - Institutional | 1 | 1.2916 |
| 4JC31 | MMTA - GI/GU - High | Late - Institutional | 2 | 1.4166 |
| 4KA11 | MMTA - Infectious - Low | Late - Institutional | 0 | 1.0070 |
| 4KA21 | MMTA - Infectious - Low | Late - Institutional | 1 | 1.0667 |
| 4KA31 | MMTA - Infectious - Low | Late - Institutional | 2 | 1.1917 |
| 4KB11 | MMTA - Infectious - Medium | Late - Institutional | 0 | 1.1422 |
| 4KB21 | MMTA - Infectious - Medium | Late - Institutional | 1 | 1.2018 |
| 4KB31 | MMTA - Infectious - Medium | Late - Institutional | 2 | 1.3269 |
| 4KC11 | MMTA - Infectious - High | Late - Institutional | 0 | 1.2535 |
| 4KC21 | MMTA - Infectious - High | Late - Institutional | 1 | 1.3131 |
| 4KC31 | MMTA - Infectious - High | Late - Institutional | 2 | 1.4382 |
| 4LA11 | MMTA - Respiratory - Low | Late - Institutional | 0 | 0.9919 |
| 4LA21 | MMTA - Respiratory - Low | Late - Institutional | 1 | 1.0515 |
| 4LA31 | MMTA - Respiratory - Low | Late - Institutional | 2 | 1.1766 |
| 4LB11 | MMTA - Respiratory - Medium | Late - Institutional | 0 | 1.1358 |
| 4LB21 | MMTA - Respiratory - Medium | Late - Institutional | 1 | 1.1954 |
| 4LB31 | MMTA - Respiratory - Medium | Late - Institutional | 2 | 1.3205 |
| 4LC11 | MMTA - Respiratory - High | Late - Institutional | 0 | 1.2449 |
| 4LC21 | MMTA - Respiratory - High | Late - Institutional | 1 | 1.3045 |
| 4LC31 | MMTA - Respiratory - High | Late - Institutional | 2 | 1.4295 |

Page 291 *Low-Utilization Payment Adjustment (LUPA) Add-On Payments and Partial Payment Adjustments under PDGM*

CMS is finalizing its proposal to continue to multiply the per-visit payment amount for the first skilled nursing, physical therapy, or speech-language pathology visit in LUPA periods that occur as the only period of care or the initial 30-day period of care in a sequence of adjacent 30-day periods of care by the appropriate add-on factor (1.8451 for SNF, 1.6700 for PT, and 1.6266 for SLP) to determine the LUPA add-on payment amount for 30-day periods of care under the PDGM.

Comment

As previously noted, the PDGM is a complex change. The material in the rule spans nearly 200 pages.

To support an assessment of the effects of the PDGM, CMS says it will provide, upon request, a Home Health Claims-OASIS Limited Data Set (LDS) file to accompany the CY 2019 HH PPS proposed and final rules. The Home Health Claims-OASIS LDS file can be requested by following the instructions on the following CMS website: <https://go.cms.gov/2KGuyY0>, and a file layout will be available.

Additionally, CMS will make available agency-level impacts and a report to congressional committees regarding a technical expert panel's insights on the proposed PDGM, as well as an interactive Grouper Tool that will allow HHAs to determine case-mix weights for their patient populations. These materials are at: <https://www.cms.gov/Center/Provider-Type/Home-Health-Agency-HHA-Center.html>.

Page 321 ***Change Regarding Remote Patient Monitoring under the Medicare Home Health Benefit***

CMS will define remote patient monitoring under the Medicare home health benefit as “the collection of physiologic data (for example, ECG, blood pressure, glucose monitoring) digitally stored and/or transmitted by the patient or caregiver or both to the home health agency.”

Additionally, CMS is finalizing its proposal to amend the regulations at 42 CFR 409.46 to include the costs of remote patient monitoring as an allowable administrative cost (that is, operating expense), if remote patient monitoring is used by the HHA to augment the care planning process.

4. Provisions of the Home Health Value-Based Purchasing (HHVBP) Model

Using a randomized selection methodology finalized in the CY 2016 HH PPS final rule, nine states were selected for inclusion in the HHVBP Model, representing each geographic area across the nation. All Medicare-certified HHAs providing services in Arizona, Florida, Iowa, Maryland, Massachusetts, Nebraska, North Carolina, Tennessee, and Washington (competing HHAs) are required to compete in the Model.

Beginning in CY 2018 based on performance on applicable measures, CMS will impose payment adjustments. Payment adjustments will be increased incrementally over the course of the HHVBP Model in the following manner: (1) A maximum payment adjustment of 3 percent (upward or downward) in CY 2018; (2) a maximum payment adjustment of 5 percent (upward or downward) in CY 2019; (3) a maximum payment adjustment of 6 percent (upward or downward) in CY 2020; (4) a maximum payment adjustment of 7 percent (upward or downward) in CY 2021; and (5) a maximum payment adjustment of 8 percent (upward or downward) in CY 2022. Payment adjustments will be based on each HHA's Total Performance Score (TPS) in a given performance year (PY) on (1) a set of measures already reported via OASIS and HHCAHPS for all patients serviced by the HHA and select claims data elements, and (2) three New Measures where points are achieved for reporting data.

For CY 2019, CMS proposed to remove five measures and add two new composite measures to the applicable measure set for the HHVBP model, revise its weighting methodology for the measures, and rescore the maximum number of improvement points.

CMS is finalizing, as proposed, the removal of the Influenza Immunization Received for Current Flu Season and Pneumococcal Polysaccharide Vaccine Ever Received measures from the set of applicable measures beginning with PY4 and subsequent years of the model.

CMS is finalizing its proposal to replace three OASIS-based measures, Improvement in Ambulation-Locomotion, Improvement in Bed Transferring, and Improvement in Bathing, with two composite measures, Total Normalized Composite Change in Self-Care and Total Normalized Composite Change in Mobility, for PY4 and subsequent performance years.

The rule's Table 38 (page 341) reflects CMS's finalized policies to remove the Influenza Immunization Received for Current Flu Season and Pneumococcal Polysaccharide Vaccine Ever Received measures and to replace the Improvement in Ambulation-Locomotion, Improvement in Bed Transferring, and Improvement in Bathing measures with the new Total Normalized Composite Change in Self-Care and Total Normalized Composite Change in Mobility measures.

5. Updates to the Home Health Quality Reporting Program (HH QRP)

This rule says that the HH QRP currently has 30 measures for the CY 2020 program year. Refer to the rule's table 41 for a list of the measures. (Display copy page 386)

CMS will remove seven measures beginning with the CY 2021 HH QRP.

1. Removal of the Depression Assessment Conducted Measure
2. Removal of the Diabetic Foot Care and Patient/Caregiver Education Implemented during All Episodes of Care Measure
3. Removal of the Multifactor Fall Risk Assessment Conducted for All Patients Who Can Ambulate (NQF #0537) Measure
4. Removal of the Pneumococcal Polysaccharide Vaccine Ever Received Measure
5. Removal of the Improvement in the Status of Surgical Wounds Measure
6. Removal of the Emergency Department Use without Hospital Readmission during the First 30 Days of HH (NQF #2505) Measure
7. Removal of the Re-hospitalization during the First 30 Days of HH (NQF #2380) Measure
8. Measure

6. Medicare Coverage of Home Infusion Therapy Services

For CYs 2019 and 2020, and as required by section 50401 of the ***Bipartisan Budget Act of 2018***, CMS is implementing a temporary transitional payment for home infusion therapy services that pays eligible home infusion therapy suppliers for associated professional services for administering certain drugs and biologicals infused through a durable medical equipment pump, training and education, and remote monitoring and monitoring services.

Section 5012 of the ***21st Century Cures Act*** created a new permanent Medicare benefit for home infusion therapy services beginning Jan. 1, 2021. This rule finalizes elements of the permanent home infusion benefit including the health and safety standards for home infusion therapy, an accreditation process for qualified home infusion therapy suppliers and an approval and oversight process for the organizations that accredit qualified home infusion therapy suppliers. Additionally, CMS says it recognizes the concerns from stakeholders and members of Congress on the agency's interpretation of "infusion drug administration calendar day", including with respect to professional services that may be provided outside of the home and, as applicable, payment amounts for such services. CMS notes it intends to ensure access to home infusion therapy services in accordance with section 50401 of the BBA of 2018.

Our Washington liaison, Larry Goldberg of Larry Goldberg Consulting, has provided us with this summary. Please contact Jeff Weegar, NCHA, at 919-677-4231, jweegar@ncha.org or Ronnie Cook, NCHA, at 919-4225, rcook@ncha.org if you have questions.